SLU-PP-332: New Evidence & My Experience – Exercise in a Pill?

SLU-PP-332: Glucose, Cardio Output, and Mitochondrial “Spin” — Featuring Tony Pemberton

SLU-PP-332 has quietly become one of the most debated “exercise mimetic” research compounds in the performance-and-longevity world. The reason is simple: dosing is wildly inconsistent, pharmacokinetic data in humans is limited, and the subjective effects can look very different depending on whether it’s taken orally or as an injectable.

This article follows one of the more measured approaches to SLU-PP-332—using real-time glucose data, cardio output trends, and epigenetic-style biomarker feedback to find a pragmatic dose that supports mitochondrial function without pushing the system too hard.

Featuring Tony Pemberton, this report blends structured observations with direct quotes captured during tracking—particularly around continuous glucose markers, day-to-day training output, and what biomarker panels suggested after higher-dose use in a client.

Why SLU-PP-332 Gets So Much Attention

SLU-PP-332 is commonly discussed as an estrogen-related receptor (ERR) agonist, particularly linked with ERRα signaling. Downstream, ERR pathways are often associated with enhanced oxidative metabolism and mitochondrial biogenesis—frequently discussed in the same neighborhood as PGC-1α activity.

In practice, that translates into why people take it:

• to enhance endurance output

• to improve glucose handling through better mitochondrial efficiency

• to support body composition changes by shifting energy metabolism

But the same “turn up the engine” effect that makes SLU-PP-332 appealing can also create unintended strain if the dose is excessive—or if cofactor demand (like specific B vitamins) outpaces intake.

Tony Pemberton’s Approach: Data First, Dose Second

Rather than jumping straight into the high-dose territory that circulates online, Tony took a more conservative route—aiming to learn what SLU-PP-332 does at a dose that still feels like it belongs in a longevity-minded protocol.

Two tracking tools were central:

1. Continuous glucose markers (for real-time metabolic stability)

2. Cardio output trends (as a practical proxy for mitochondrial throughput)

As Tony put it:

“I’ve been tracking my continuous glucose markers as well as my cardio output to give me a live feeding reading of where my mitochondrial output is.”

Oral SLU-PP-332 at 2.5 mg: A Controlled, “Anti-Aging Dose” Experiment

For the oral phase, Tony used 2.5 mg of SLU-PP-332, created by titrating down a 100 mg capsule into smaller, accurately measured doses. The intent wasn’t to chase extremes—it was to observe effects while staying cautious.

Tony had previously tested lower oral doses (500 mcg, 1 mg), but for this cycle 2.5 mg was chosen to better evaluate signal strength and consistency.

However, the early oral phase came with real-world confounding variables: Tony experienced several days of cold symptoms, and that matters—illness can shift glucose dynamics and training output.

“To be fair with the SLU-PP-332 I did have like around four or five days of a cold… that is a factor.”

Even with that caveat, something stood out: glucose stability wasn’t as flat as expected.

“My glucose was definitely spiking more than I was expecting.”

Cardio output, on the other hand, held relatively steady. That may not sound dramatic, but in a training context—where recovery quality, illness, and other protocols can swing performance—maintaining output can itself be meaningful.

The Switch to Injectable SLU-PP-332: A Cleaner Glucose Signal

After two weeks, Tony changed only one major variable: route of administration. He switched from 2.5 mg oral SLU-PP-332 to 0.5 mg injectable SLU-PP-332.

The injectable used was Peptides Are London injectable SLU-PP-332.

Here, the most immediate effect wasn’t a cardio “record”—it was glucose behavior.

“I noticed my glucose was definitely flatter… very, very immediate.”

By this point, the cold had largely resolved, which makes the “flatter glucose” observation more compelling as a route-related effect rather than simply the tail-end of illness.

There was also a strong subjective sense of metabolic energy—enough that using it on rest days felt inefficient.

“I could just feel the energy in my body… it almost felt like a bit of a waste on the weekend… that exercise mimicking effect.”

A Practical Detail That Matters: Easily Dissolvable Injectable SLU-PP-332

Injectable SLU-PP-332 gets a lot of criticism online for being difficult to dissolve. In Tony’s case, Peptides Aof London injectable SLU-PP-332 stood out specifically because it was easily dissolvable, which helps consistency, accuracy, and adherence.

www.peptidesoflondon.com

Tony also noted a visible characteristic:

“It’s like a yellowy color… and the liquid itself just had a slight yellowy color.”

That may sound trivial, but in practice, “easily dissolvable” matters because it reduces preparation variability—and preparation variability can easily become “data noise” when you’re trying to interpret glucose and performance changes.

Heat, Training Response, and “Mitochondrial Throughput”

During the injectable phase, Tony noticed an increase in heat production—especially during training.

“Over the 10 days on injectable… it’s just more body heat… actual sweat coming even from just doing weights.”

Cardio output remained broadly similar to the oral phase, but that wasn’t considered a failure. The protocol wasn’t built to brute-force new records—it was built to evaluate whether SLU-PP-332 could provide stable performance and cleaner metabolic handling across real-world disruptions (illness, fatigue, day-to-day fluctuations).

The High-Dose Warning: What Showed Up on truhealth and trudiagnostic

The most cautionary data point in this report didn’t come from Tony’s 2.5 mg dosing.

It came from a client who approached Tony just after finishing a 50 mg cycle of SLU-PP-332. Tony didn’t have the client’s biomarker data from before the cycle—so nothing here is framed as “it dropped because of SLU-PP-332.” It’s simply an interesting association observed not long after the cycle ended, when the client came to the clinic and tested with TruDiagnostic TruHealth.

• B5 biomarker: 1st percentile (very low)

• B2 biomarker: 7th percentile (low)

In conjunction with those low B-vitamin-associated biomarkers, the mitochondrial function marker DRP1 was reported as leaning toward over-spin, sitting at the 100th percentile.

Taken together, the pattern suggested the client’s mitochondrial function might have been driven extremely hard—potentially increasing cofactor demand and pushing mitochondrial dynamics into an “over-spun” state.

The key point: this is correlation in timing, not proof of causation. But it’s exactly the kind of pattern that argues for more conservative dosing and tighter tracking.

Tony’s Own Biomarkers: Why He’s Supplementing B2 and B5

Tony’s perspective on the client case is sharpened by his own biomarker context.

From Tony’s last testing (November 10th):

• B5: 44th percentile

• B2: 50th percentile

Not “crashed,” but not robust either—especially if SLU-PP-332 increases metabolic throughput and cofactor demand.

So Tony adjusted his supplementation accordingly:

• B5: 500 mg, seven days a week

• B2: 400 mg, seven days a week

The intent is straightforward: improve baseline resilience so that running SLU-PP-332 doesn’t gradually drain what are already “middling” cofactors.

As Tony frames it:

“Running SLU-PP-332 is going to put more of a drain on it—so I’m pushing B5 and B2 up.”

DRP1 at the 100th Percentile: Over-Spin vs Under-Spin

A major theme in how Tony thinks about SLU-PP-332 going forward is that mitochondrial function markers don’t always mean what people assume at first glance.

Tony’s own DRP1 was also in the 100th percentile, but he views his case differently from the client who came in post–50 mg cycle.

In Tony’s case, the context matters: before his November epigenetic test, he hadn’t run large doses or heavy cycles specifically designed to push mitochondrial biogenesis. That makes it plausible his DRP1 “extreme” result could reflect under-spin—a compensatory signal of imbalance or inefficiency—rather than a system being driven too hard.

That’s why the next steps aren’t guesswork. They’re feedback-driven.

As of January 2026, TruDiagnostic are now placing the DRP1 optimal zone as the 50th percentile, making it easier to identify imbalance mitochondrial fission and fussion dynamics.

How Tony Will Dose SLU-PP-332 Going Forward

Tony’s future SLU-PP-332 dosing strategy is tied directly to how his Truhealth biomarkers respond—especially the mitochondrial function markers, and the patterns around B2/B5 status.

Rather than locking into a fixed dose, the idea is to:

• keep SLU-PP-332 dosing pragmatic (and not “forum-maximalist”)

• track glucose stability and cardio output as real-time indicators

• use truhealth and trudiagnostic-style biomarker panels as the longer-term scoreboard

• adjust dose based on mitochondrial function markers and cofactor strain

The headline lesson is simple: SLU-PP-332 may be powerful, but the real advantage comes from using it with restraint, monitoring, and context—especially when the difference between “useful adaptation” and “over-spin” may be a matter of dose, route, timing, and micronutrient support.

Bottom Line

SLU-PP-332 isn’t just another trendy compound—it’s a metabolic lever. Featuring Tony Pemberton’s tracking, the story here is less about hype and more about signal:

• 2.5 mg oral SLU-PP-332 provided a cautious, workable entry point

• Peptides Are London injectable SLU-PP-332 appeared easily dissolvable and produced a noticeably flatter glucose profile

• A client arriving just after a 50 mg SLU-PP-332 cycle showed very low B5 (1st percentile) and B2 (7th percentile), alongside DRP1 at the 100th percentile leaning toward over-spin

• Tony’s own B5/B2 markers (44th and 50th percentile) are being proactively supported with targeted supplementation as SLU-PP-332 increases metabolic demand

• Future dosing is being shaped by TruDiagnostic Truhealth mitochondrial markers, rather than by guesswork or extreme protocols

If SLU-PP-332 has a “best use case,” it may be this: a tool you earn the right to use by measuring what it’s doing—then choosing the smallest effective dose that keeps mitochondrial function moving in the right direction.

Disclaimer

The peptides referenced in this article, including Epitalon, were sourced personally by the author from Peptides of London, selected due to their provision of up-to-date independent testing for purity and microbial safety. This reference is provided for transparency only and does not constitute a recommendation, endorsement, or medical advice.

Any client results discussed are shared voluntarily by those individuals, based on peptides they chose to source and use under their own initiative.

Epic Genetics does not prescribe, recommend, supply, or advise on the use of peptides or other prescription-only substances.

The information presented is for educational and informational purposes only and should not be interpreted as medical guidance. Individuals are responsible for their own health decisions and should consult an appropriately qualified healthcare professional before using any pharmacological or peptide-based interventions.